Why is Titan Biotech falling/rising?

As of 16-Jul, Titan Biotech Ltd's stock price is currently at 455.30, reflecting a slight increase of 0.7, or 0.15%. The stock has outperformed its sector by 0.3% today, with a delivery volume that has risen by 7.39% compared to the 5-day average, indicating increased investor participation. However, despite a positive performance over the past month with a return of 6.68%, the stock has significantly underperformed in the year-to-date period, showing a decline of 37.86%. The company has a high management efficiency with a return on equity (ROE) of 25.08% and a low debt-to-equity ratio, but it has also reported negative results for the last three consecutive quarters, which raises concerns about its long-term growth potential.
In the broader market context, while the Sensex has declined by 1.08% over the past week, Titan Biotech's short-term performance has been relatively stable. However, the stock has underperformed the market over the last year, generating a return of -25.23% compared to the BSE500's positive return of 0.47%. This underperformance, coupled with a high valuation compared to peers and declining profits, suggests that while there may be short-term gains, the long-term outlook remains uncertain, contributing to the stock's volatility in the market.